

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CSPC PHARMACEUTICAL GROUP LIMITED

### 石藥集團有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### INSIDE INFORMATION

#### PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2023

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC Innovation**”) is a subsidiary of the Company and its shares are listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765). In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC Innovation has published its 2023 Annual Report (“**Annual Report**”) on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the appendices of this announcement (the “**Appendices**”) which set out the principal financial information of CSPC Innovation prepared in accordance with the PRC Accounting Standard for Business Enterprises for the year ended 31 December 2023.

The information in the Appendices is an extract of the Annual Report in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 15 March 2024

*As at the date of this announcement, the board of directors of the Company comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*

**APPENDIX I**  
**PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS**

*Unit: RMB Yuan*

	<b>2023</b>	<b>2022</b>	<b>Increase/decrease compared with last year</b>	<b>2021</b>
Revenue (Yuan)	2,501,699,905.93	2,626,488,832.63	-4.75%	1,849,677,007.18
Net profit attributable to listed company's shareholders (Yuan)	755,557,253.28	726,277,891.97	4.03%	393,228,489.93
Net profit attributable to listed company's shareholders excluding non-recurring gain/loss (Yuan)	743,672,985.61	657,608,747.31	13.09%	298,498,249.98
Net cash flows arising from operating activities (Yuan)	927,241,226.87	640,717,518.79	44.72%	292,085,994.15
Basic earnings per share (Yuan/share)	0.6533	0.6519	0.21%	0.3530
Diluted earnings per share (Yuan/share)	0.6533	0.6519	0.21%	0.3530
Weighted average return on net assets	16.23%	20.11%	-3.88%	13.41%
	<b>End of 2023</b>	<b>End of 2022</b>	<b>Increase/decrease compared with the end of last year</b>	<b>End of 2021</b>
Total assets (Yuan)	5,632,123,851.51	4,584,035,512.38	22.86%	3,741,208,950.36
Net assets attributable to listed company's shareholder (Yuan)	5,078,808,635.08	3,935,600,634.14	29.05%	3,289,370,322.06

## APPENDIX II NON-RECURRING GAIN/LOSS ITEMS AND AMOUNTS

*Unit: RMB Yuan*

Items	Amounts in 2023	Amounts in 2022	Amounts in 2021	Descriptions
Gain/loss from disposal of non-current assets (including the part offset with the provision for impairment of assets)	-1,819,411.71	-4,562,657.58	-7,384,221.62	
Government grants recognised in profit or loss of current period (excluding those closely related to the company's normal operating business, complied with national policies and regulations, granted according to determined standards, and continuously affecting the company's gain/loss)	13,821,721.77	4,865,650.37	18,300,150.56	
Gain/loss from entrusted investments or assets management		6,517,950.19	10,618,573.52	
Net current profit or loss of subsidiaries from the beginning of the period to the consolidation date arising from consolidation of companies under common control		63,201,256.20	76,157,058.94	
Other non-operating income and expenses other than the above items	2,143,922.54	59,880.88	-898,539.74	
Other items of profit or loss falling within the definition of non-recurring gains and losses			3,380,349.16	
Less: Impacts of income tax	2,352,729.90	1,413,003.18	5,421,843.96	
Impact of minority interests (after tax)	-90,764.97	-67.78	21,286.91	
Total	11,884,267.67	68,669,144.66	94,730,239.95	—

### APPENDIX III SIGNIFICANT CHANGES IN ASSETS COMPONENTS

*Unit: RMB Yuan*

	End of 2023		Beginning of 2023		Percentage increase/decrease	Description on significant changes
	Amount	Percentage of total asset	Amount	Percentage of total asset		
Cash and bank balances	3,422,172,812.61	60.76%	2,195,684,427.95	47.90%	12.86%	Mainly due to the increase in cash and bank balances received by the company for goods sold and the receipt of funds raised by the company.
Trade receivables	392,376,024.64	6.97%	481,379,233.73	10.50%	-3.53%	No significant change
Inventories	223,684,616.72	3.97%	238,125,791.53	5.19%	-1.22%	No significant change
Long-term equity investments	267,068,968.17	4.74%	253,488,895.12	5.53%	-0.79%	No significant change
Fixed assets	995,410,727.44	17.67%	984,018,362.29	21.47%	-3.80%	No significant change
Construction in progress	62,151,577.88	1.10%	70,735,076.79	1.54%	-0.44%	No significant change
Right-of-use assets	1,612,974.52	0.03%			0.03%	No significant change
Contract liabilities	19,803,395.73	0.35%	68,259,661.19	1.49%	-1.14%	No significant change
Long-term borrowings			19,800,000.00	0.43%	-0.43%	Mainly due to the decrease in bank borrowing of CSPC Shengxue.
Lease liabilities	841,216.40	0.01%			0.01%	No significant change